4D Molecular Therapeutics, Inc. Earnings Per Share (Basic)
4D Molecular Therapeutics, Inc. (FDMT) reported Earnings Per Share (Basic) of -$1.04 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.04.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$1.01.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $0.30.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.01.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.42.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$2.98.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.58.
- 4D Molecular Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$3.32.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.04 10-Q · filed 2026-08-13 | -$2.05 10-Q · filed 2026-08-13 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.77 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$1.01 10-Q · filed 2026-05-07 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.69 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.64 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | $0.30 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.42 10-K · filed 2026-03-18 |
| 2025-09-30 | -$1.01 10-Q · filed 2025-11-10 | -$1.99 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.85 10-Q · filed 2025-11-10 | -$3.74 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.98 10-Q · filed 2026-08-13 | -$1.84 10-Q · filed 2026-08-13 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.52 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.86 10-Q · filed 2026-05-07 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.54 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.18 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$2.98 10-K · filed 2026-03-18 |
| 2024-09-30 | -$0.79 10-Q · filed 2025-11-10 | -$1.42 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$2.08 10-Q · filed 2025-11-10 | -$2.83 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-06-30 | -$0.63 10-Q · filed 2025-08-11 | -$1.29 10-Q · filed 2025-08-11 | -$2.03 derived: net income ÷ weighted average shares · filed 2025-08-11 | -$2.32 derived: net income ÷ weighted average shares · filed 2025-08-11 |
| 2024-03-31 | -$0.66 10-Q · filed 2025-05-08 | -$1.40 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$1.67 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$2.42 derived: net income ÷ weighted average shares · filed 2025-05-08 |
| 2023-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$1.00 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$1.75 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$2.58 10-K · filed 2025-02-28 |
| 2023-09-30 | -$0.24 10-Q · filed 2024-11-13 | -$0.99 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.81 10-Q · filed 2024-11-13 | -$2.63 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.77 10-Q · filed 2024-08-08 | -$1.63 10-Q · filed 2024-08-08 | -$2.48 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$3.28 derived: net income ÷ weighted average shares · filed 2024-08-08 |
| 2023-03-31 | -$0.88 10-Q · filed 2024-05-09 | -$1.72 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$2.51 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$3.38 derived: net income ÷ weighted average shares · filed 2024-05-09 |
| 2022-12-31 | -$0.84 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.64 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$2.50 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$3.32 10-K · filed 2024-02-29 |
| 2022-09-30 | -$0.79 10-Q · filed 2023-11-09 | -$1.66 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.48 10-Q · filed 2023-11-09 | -$3.30 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.87 10-Q · filed 2023-08-09 | -$1.69 10-Q · filed 2023-08-09 | -$2.51 derived: net income ÷ weighted average shares · filed 2023-08-09 | -$3.33 derived: net income ÷ weighted average shares · filed 2023-08-09 |
| 2022-03-31 | -$0.82 10-Q · filed 2023-05-11 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.46 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.79 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.82 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.65 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.96 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$2.57 10-K · filed 2023-03-15 |
| 2021-09-30 | -$0.82 10-Q · filed 2022-11-08 | -$1.11 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.72 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.28 10-Q · filed 2022-08-11 | -$0.90 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |